SVCM
Saturn V Capital Management Portfolio holdings
AUM
$247M
This Quarter Return
+11.46%
1 Year Return
+2.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$247M
AUM Growth
+$247M
(+25%)
Cap. Flow
+$28.4M
Cap. Flow
% of AUM
11.52%
Top 10 Holdings %
Top 10 Hldgs %
69.44%
Holding
26
New
5
Increased
10
Reduced
9
Closed
2
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$22M |
| 2 |
Dyne Therapeutics
DYN
|
$13.9M |
| 3 |
Vaxcyte
PCVX
|
$10.1M |
| 4 |
LENZ
LENZ Therapeutics
LENZ
|
$10M |
| 5 |
Neurocrine Biosciences
NBIX
|
$7.31M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$27.8M |
| 2 |
Disc Medicine
IRON
|
$6.46M |
| 3 |
Merus
MRUS
|
$5.2M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$5.06M |
| 5 |
SLN
Silence Therapeutics
SLN
|
$4.05M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Jazz Pharmaceuticals
JAZZ
$7.75B
| $22M | 8.9% | +206,952 | New | +$22M |
|
|
2
Disc Medicine
IRON
$2.07B
| $21M | 8.5% | 396,115 -122,062 | -24% | -$6.46M |
|
3
Amylyx Pharmaceuticals
AMLX
$836M
| $20.9M | 8.47% | 3,260,570 +834,134 | +34% | +$5.35M |
|
|
4
Vaxcyte
PCVX
$4B
| $17.7M | 7.17% | 544,221 +311,926 | +134% | +$10.1M |
|
5
Cogent Biosciences
COGT
$1.69B
| $16.5M | 6.69% | 2,297,524 +817,504 | +55% | +$5.87M |
|
6
Celcuity
CELC
$2.17B
| $15.8M | 6.41% | 1,185,520 +91,843 | +8% | +$1.23M |
|
7
CG Oncology
CGON
$2.04B
| $15.3M | 6.18% | 586,647 +8,951 | +2% | +$233K |
|
8
Xenon Pharmaceuticals
XENE
$2.98B
| $14.7M | 5.94% | 468,364 +54,653 | +13% | +$1.71M |
|
|
9
Dyne Therapeutics
DYN
$1.92B
| $13.9M | 5.62% | +1,455,429 | New | +$13.9M |
|
10
MoonLake Immunotherapeutics
MLTX
$3.54B
| $13.7M | 5.56% | 290,784 -53,065 | -15% | -$2.5M |
|
|
11
Merus
MRUS
$4.98B
| $11.8M | 4.78% | 224,260 -98,951 | -31% | -$5.2M |
|
|
CNTA
12
Centessa Pharmaceuticals
CNTA
$2.25B
| $10.4M | 4.22% | 793,327 +344,635 | +77% | +$4.53M |
|
|
LENZ
13
LENZ Therapeutics
LENZ
$1.1B
| $10M | 4.07% | +342,312 | New | +$10M |
|
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $7.31M | 2.96% | +58,181 | New | +$7.31M |
|
15
Ocular Therapeutix
OCUL
$2.12B
| $6.76M | 2.74% | 728,576 +130,385 | +22% | +$1.21M |
|
|
16
Ascendis Pharma
ASND
$11.8B
| $6.59M | 2.67% | 38,191 -161,073 | -81% | -$27.8M |
|
17
argenx
ARGX
$43.6B
| $5.67M | 2.3% | 10,285 -3,577 | -26% | -$1.97M |
|
|
ABVX
18
Abivax
ABVX
$6.12B
| $4.76M | 1.93% | 622,479 +69,553 | +13% | +$532K |
|
|
19
Syndax Pharmaceuticals
SNDX
$1.41B
| $4.69M | 1.9% | 500,551 -540,729 | -52% | -$5.06M |
|
20
NewAmsterdam Pharma
NAMS
$2.71B
| $4M | 1.62% | 220,695 +104,342 | +90% | +$1.89M |
|
|
CTNM
21
Contineum Therapeutics
CTNM
$293M
| $1.27M | 0.51% | 319,348 -241,631 | -43% | -$959K |
|
22
Replimune Group
REPL
$422M
| $1.2M | 0.49% | +128,917 | New | +$1.2M |
|
23
KalVista Pharmaceuticals
KALV
$678M
| $710K | 0.29% | 62,793 -192,267 | -75% | -$2.17M |
|
|
SLN
24
Silence Therapeutics
SLN
$227M
| $201K | 0.08% | 34,737 -697,726 | -95% | -$4.05M |
|
25
Crinetics Pharmaceuticals
CRNX
$2.92B
| – | – | -59,017 | Closed | -$1.98M |
|